Elderly-onset gout: A review

Rheumatology International

Volumn 28, Issue 1, 2007, Pages 1-6

  De Leonardis, Francesco ^a   Govoni, Marcello ^a   Colina, Matteo ^a   Bruschi, Marco ^a   Trotta, Francesco ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

Diuretics; Elderly onset; Gout; Hyperuricemia; Tophi

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; COLCHICINE; CREATININE; DIURETIC AGENT; FEBUXOSTAT; FENOFIBRATE; INDOMETACIN; NONSTEROID ANTIINFLAMMATORY AGENT; PEGYLATED URICASE; PREDNISONE; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG; URATE; URIC ACID; XANTHINE OXIDASE INHIBITOR;

ALLERGIC REACTION; ARTHROPATHY; CARDIOTOXICITY; CLINICAL PRACTICE; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; CREATININE CLEARANCE; DEMOGRAPHY; DIET RESTRICTION; DISEASE ASSOCIATION; DISEASE COURSE; DOSE KIDNEY FUNCTION RELATION; EPIDEMIOLOGICAL DATA; GASTROINTESTINAL TOXICITY; GOUT; HAND; HUMAN; HYPERLIPIDEMIA; HYPERURICEMIA; KIDNEY DYSFUNCTION; LOW DRUG DOSE; MENOPAUSAL SYNDROME; MYOPATHY; NEPHROTOXICITY; ONSET AGE; OSTEOARTHRITIS; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; RASH; REVIEW; RISK FACTOR; SEX RATIO; URIC ACID URINE LEVEL; URINARY EXCRETION;

AGE FACTORS; AGED; AGED, 80 AND OVER; DIURETICS; FEMALE; GOUT; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; MALE; PREVALENCE; RISK FACTORS; SEX FACTORS; URIC ACID;

EID: 34848871559     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-007-0421-7     Document Type: Review

References (61)

1. Ene-Stroescu D, Gorbien MJ (2005) Gouty arthritis. A primer on late-onset gout. Geriatrics 60:24-31
2. Mikuls TR, Farrar JT, Bilker WB, Fernandes S, Schumacher HR Jr, Saag KG (2005) Gout epidemiology: results from the UK general practice research database, 1990-1999. Ann Rheum Dis 64:267-272
3. Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH, Heyse SP, Hirsch R, Hochberg MC, Hunder GG, Liang MH, Pillemer SR, Steen VD, Wolfe F (1998) Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 41:778-799
4. Wallace KL, Riedel AA, Joseph-Ridge N, Wortmann R (2004) Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol 31:1582-1587
5. Arromdee E, Michet JC, Crowson CS, O'Fallon WM, Gabriel S (2002) Epidemiology of gout: is the incidence rising? J Rheumatol 29:2403-2406
6. Kim KY, Schumacher RH, Hunsche E, Wertheimer AI, Kong SX (2003) A literature review of the epidemiology and treatment of acute gout. Clin Ther 25:1593-1617
7. Harrold LR, Yood R, Milkus TR, Andrade S, Davis J, Fuller K, Chan A, Roblin D, Raebel M, Von Worley A, Platt R, Saag K (2006) Sex differences in gout epidemiology: evaluation and treatment. Ann Rheum Dis 65:1368-1372
8. De Souza AW, Fernandes V, Ferrari AJ (2005) Female gout: clinical and laboratory features. J Rheumatol 32:2186-2188
9. Effectiveness of interventions for the treatment of acute and prevention of recurrent gout - a systematic review. Rheumatology 2006;45:1422-1431
10. Renal function in gout. IV. An analysis of 524 gouty subjects including long-term follow-up studies. Am J Med 1975;59:605-613
11. Ter Borg EJ, Rasker JJ (1987) Gout in the elderly, a separate entity? Ann Rheum Dis 46:72-76
12. MacFarlane DG, Dieppe PA (1985) Diuretic-induced gout in elderly women. Br J Rheumatol 24:155-157
13. Puig JG, Michan AD, Jimenez ML, Perez de Ayala C, Mateos FA, Capitan CF, de Miguel E, Gijon JB (1991) Female gout. Clinical spectrum and uric acid metabolism. Arch Intern Med 151:726-732
14. Gurwitz JH, Kalish SC, Bohn RL, Glynn RJ, Monane M, Mogun H, Avorn J (1997) Thiazide diuretics and the initiation of anti-gout therapy. J Clin Epidemiol 50:953-959
15. Hunter DJ, York M, Chaisson CE, Woods R, Niu J, Zhang Y (2006) Recent diuretic use and the risk of recurrent gout attacks: the online case-crossover gout study. J Rheumatol 33:1341-1344
16. Scott JT, Higgen CS (1992) Diuretic induced gout: a multifactorial condition. Ann Rheum Dis 51:259-261
17. Janssens HJEM, van de Linsdonk EH, Janssen M, van den Hoogen HJM, Verbeek ALM (2006) Gout, not induced by diuretics? A case-control study from primary care. Ann Rheum Dis 65:1080-1083
18. Fang J, Alderman MH (2000) Serum uric acid and cardiovascular mortality. The NHANES 1 epidemiologic follow-up study, 1971-1992. JAMA 283:2404-2410
19. Culleton BF, et al (1999) Serum uric acid and risk for cardiovascular disease and death: the Framingham heart study. Ann Int Med 131:7-13
20. Hall AP, Barry PE, Dawber TR, McNamara PM (1967) Epidemiology of gout and hyperuricemia: a long term population study. Am J Med 42:27-37
21. Chen SY, Chen CL, Shen ML (2007) Manifestations of metabolic syndrome associated with male gout in different age strata. Clin Rheumatol January 26. doi: 10.1007/s10067-006-0527-4 (in press)
22. Krishnan E, Baker JF, Furst DE, Schumacher HR (2006) Gout and the risk of acute myocardial infarction. Arthitis Rheum 8:2688-2696
23. Wernick R, Winkler C, Campbell S (1992) Tophi as the initial manifestation of gout. Report of six cases and review of the literature. Arch Intern Med 152:873-876
24. Doherty M, Dieppe P (1986) Crystal deposition disease in the elderly. Clin Rheum Dis 2:97-116
25. Foldes K, Petersilge CA, Weisman MH, Resnick D (1996) Nodal ostheoarthritis and gout: a report of four new cases. Skeletal Radiol 25:421-424
26. Simkin PA, Campbell PM, Larson EB (1983) Gout in Heberden's nodes. Arthritis Rheum 26:94-97
27. Gerster JC, Landry M, Dufresne L, Meuwly JY (2002) Imaging of tophaceus gout: computed tomography provides specific images compared with magnetic resonance imaging and ultrasonography. Ann Rheum Dis 61:52-54
28. Lopez Redondo MJ, Requena L, Macia M, Schoendorff C, Sanchez Yus E, Robledo A (1993) Fingertip tophi without gouty arthritis. Dermatology 187:140-143
29. Chopra KF, Schneiderman P, Grossman ME (1999) Finger pad tophi. Cutis 64:233-236
30. Bomalaski JS, Schumacher HR (1984) Podagra is more than gout. Bull Rheum Dis 34:1-8
31. Kozin F, McCarty DJ (1977) Rheumatoid factors in the serum of gouty patients (letter). Arthritis Rheum 20:1559-1560
32. Zhang W, Doherty M, Pascal E, Bardin T, Barskova V, Conaghan P, Gerster J, Jacobs J, Leeb B, Liote F, McCarthy G, Netter P, Nuki G, Perez-Ruiz F, Pignone A, Pimentao J, Punzi L, Roddy E, Uhlig T, Zimmermann-Gorska I (2006) Eular evidence based recommendations for gout - part I. Diagnosis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 65:1301-1311
33. Zhang W, Doherty M, Pascal E, Bardin T, Barskova V, Conaghan P, Gerster J, Jacobs J, Leeb B, Liote F, McCarthy G, Netter P, Nuki G, Perez-Ruiz F, Pignone A, Pimentao J, Punzi L, Roddy E, Uhlig T, Zimmermann-Gorska I (2006) Eular evidence based recommendations for gout - part II. Management: report of task force of the EULAR standing committee for international clinical studies including therapeutics. Ann Rheum Dis 55:1312-1324
34. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J (2006) Gout-associated crystals activate the NALP3 inflammasome. Nature 440:237-241
35. Chun CJ, Shi Y, Hearn A, Fitzgerald K, Golenbock D, Reed G, Akira S, Rock KL (2006) My D88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urate crystals. J Clin Invest 116:2262-2271
36. Spilberg I, Mandell B, Mehta J, Simchowitz L, Rosenberg D (1979) Mechanism of action of colchicine in acute urate crystal-induced arthritis. J Clin Invest 64:775-780
37. Roberge CJ, Gaudry M, de Medicis R, Lussier A, Poubelle PE, Naccache PH (1993) Crystal-induced neutrophil activation. IV. Specific inhibition of tyrosine phosphorylation by colchicine. J Clin Invest 92:1722-1729
38. Wilbur K, Makowsky M (2004) Colchicine myotoxicity: case reports and literature review. Pharmacotherapy 24:1784-1792
39. Groff GD, Franck WA, Raddatz DA (1990) Systemic steroid therapy for acute gout: a clinical trial and review of the literature. Semin Arthritis Rheum 19:329-336
40. Fernandez C, Noguera R, Gonzalez JA, Pascual E (1999) Treatment of acute attacks of gout with a small dose of intraarticular triamcinolone acetonide. J Rheumatol 26:2285-2286
41. Arellano F, Sacristan JA (1993) Allopurinol hypersensitivity syndrome: a review. Ann Pharmacother 27:337-343
42. Hande KR, Noone RM, Stone WJ (1984) Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 76:47-56
43. Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Palo WA, Eustace D, Vernillet L, Joseph-Ridge N (2005) Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. Arthritis Rheum 52:916-923
44. Schumacher H, Becker M, Wortmann RL, MacDonald PA, Palo WA, Eustace D, Vernillet L, Joseph-Ridge N (2005) Febuxostat vs allopurinol and placebo in subjects with hyperuricemia and gout: the 28-week APEX study. Arthritis Rheum 52:S680
45. Ganson NJ, Kelly SJ, Scarlett E, Sundy JS, Hershfield MS (2006) Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase. Arthritis Res Care 8:R12
46. Schumacher HR Jr, Chen LX (2006) Newer therapeutic approaches: gout. Rheum Clin Dis North Am 32:235-244
47. Hoskison TK, Wortmann RL (2006) Advances in the management of gout and hyperuricemia. Scand J Rheumatol 35:251-260
48. Puig JG, Mateos F, Buno A, Ortega R, Rodriguez F, Dal-Re R (1999) Effect of eprosartan and losartan on metabolism in patients with essential hypertension. J Hypertens 17:1033-1039
49. Wurzner G, Gerster JC, Chiolero A, Maillard M, Fallab-Stubi CL, Brunner HR, Burnier M (2001) Comparative effects of losartan and irbesartan on serum in hypertensive patients with hyperuricaemia and gout. J Hypertens 19:1855-1860
50. Schmidt A, Gruber U, Bohmig G, Koller E, Mayer G (2001) The effect of ACE inhibitor and angiotensin II receptor antagonist therapy on serum levels and potassium homeostasis in hypertensive renal transplant recipients treated with CsA. Nephrol Dial Transplant 16:1034-1037
51. Bastow MD, Durrington PN, Ishola M (1988) Hypertriglyceridemia and hyperuricemia: effects of two fibric acid derivatives (bezafibrate and fenofibrate) in a double-blind, placebo-controlled trial. Metabolism 37:217-220
52. Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G (2004) Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med 350:1093-1103
53. Choi HK, Liu S, Curhan G (2005) Intake of purine-rich foods, protein, and dairy products and relationship to serum levels of uric acid: the third national health and nutrition examination survey. Arthritis Rheum 52:283-289
54. Lee SJ, Terkeltaub RA, Kavanaugh A (2006) Recent developments in diet and gout. Curr Opin Rheumatol 18:193-198
55. Milkus TR, Kenneth GS (2006) New insights into gout epidemiology. Curr Opin Rheumatol 18:199-203
56. Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G (2004) Alcohol intake and risk of incident gout in men: a prospective study. Lancet 363:1277-1281
57. Loenen HM, Eshuis H, Lowik MR, Schouten EG, Hulshof KF, Odink J, Kok FJ (1990) Serum uric acid correlates in elderly men and women with special reference to body composition and dietary intake (Dutch nutrition surveillance system). J Clin Epidemiol 43:1297-1303
58. Nicholls A, Scott JY (1972) Effect of weight-loss on plasma and urinary levels of uric acid. Lancet 2:1223-1224
59. Yamashita S, Matsuzawa Y, Tokunaga K, Fujioka S, Tarui S (1986) Studies on the impaired metabolism of uric acid in obese subjects: marked reduction of renal urate excretion and its improvement by a low-calorie diet. Int J Obes 10:255-264
60. Dessein PH, Shipton EA, Stanwix AE, Joffe BI, Ramokgadi J (2000) Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study. Ann Rheum Dis 59:539-543
61. Choi HK, Atkinson K, Karlson EW, Curhan G (2005) Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study. Arch Intern Med 165:742-748